Salt-inducible kinase 2 regulates fibrosis during bleomycin-induced lung injury.

ABSTRACT: Idiopathic pulmonary fibrosis is a progressive and normally fatal disease with limited treatment options. The tyrosine kinase inhibitor nintedanib has recently been approved for the treatment of idiopathic pulmonary fibrosis, and its effectiveness has been linked to its ability to inhibit a number of receptor tyrosine kinases including the platelet-derived growth factor, vascular endothelial growth factor, and fibroblast growth factor receptors. We show here that nintedanib also inhibits salt-inducible kinase 2 (SIK2), with a similar IC₅₀ to its reported tyrosine kinase targets. Nintedanib also inhibited the related kinases SIK1 and SIK3, although with 12-fold and 72-fold higher IC₅₀s, respectively. To investigate if the inhibition of SIK2 may contribute to the effect

SUBMITTER: van Gijsel-Bonnello M 

PROVIDER: S-EPMC9706632 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature